<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066685</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258AUS18</org_study_id>
    <nct_id>NCT05066685</nct_id>
  </id_info>
  <brief_title>Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program</brief_title>
  <official_title>Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD&#xD;
      who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was&#xD;
      generated to describe their baseline demographic and clinical characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD&#xD;
      who enrolled in the brolucizumab Patient Support Services (PSS) program.&#xD;
&#xD;
      PSS data was obtained from patients with wet AMD who enrolled in the program for the index&#xD;
      period 10/10/2019 to 04/30/2020.&#xD;
&#xD;
        -  Identification period of the index period: 10/10/2019 to 04/30/2020&#xD;
&#xD;
        -  Index date: Date of enrollment in the PSS program&#xD;
&#xD;
        -  Study Period: 10/10/2019 to 04/30/2020&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Actual">September 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Primary plan type</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>Age information of patients enrolled in the brolucizumab PSS program was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>Gender information of patients enrolled in the brolucizumab PSS program was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient region (by state)</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>Distribution of patients across US states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider region (by state)</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>Number of providers and their distribution across US states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insurance coverage</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>The insurance coverage details for all the patients with wet AMD was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Secondary plan type</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Status</measure>
    <time_frame>Index date defined as the date of enrollment in the PSS program</time_frame>
    <description>The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18457</enrollment>
  <condition>Age-related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>All participants</intervention_name>
    <description>All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study included patients with wet AMD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients were enrolled in the brolucizumab PSS program&#xD;
&#xD;
          -  ≥19 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-1080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17866</url>
    <description>Results for CRTH258AUS18 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary plan,</keyword>
  <keyword>AMD characteristics,</keyword>
  <keyword>brolucizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

